⚕ GalenOps CRO console
← 709 (USA)

709-1326

completed
Study: Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. Phase II · Site: 709 (USA) (Dr. Novak) · consented 2013-04-05
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
–

Adverse events

moderate assessed 2026-08-18

Moderate APPLICATION SITE BLEEDING — outcome: RECOVERED/RESOLVED; onset 2013-06-07 (study day 64.0); relationship: PROBABLE

mild assessed 2026-08-18

Mild APPLICATION SITE DERMATITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-01 (study day 27.0); relationship: PROBABLE

mild assessed 2026-08-18

Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-01 (study day 27.0); relationship: PROBABLE

mild assessed 2026-08-18

Mild COUGH — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-07-12 (study day 99.0); relationship: NONE

mild assessed 2026-08-18

Mild SYNCOPE — outcome: RECOVERED/RESOLVED; onset 2013-05-21 (study day 47.0); relationship: POSSIBLE; serious criteria: hospitalization

mild assessed 2026-08-18

Mild VOMITING — outcome: RECOVERED/RESOLVED; onset 2013-05-21 (study day 47.0); relationship: POSSIBLE

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.